Investment Rating - The report indicates a weak performance in the cosmetics and medical beauty sector, with the Shenwan Beauty Care Index declining by 1.6% from December 5 to December 12, 2025, underperforming the market [3][4]. Core Insights - The cosmetics sector faced pressure in November, with overall GMV in the Taobao system showing weakness due to the pre-promotion of the Double 11 sales event and the rise of Douyin as a sales channel. Brands like Han Shu and Lin Qingxuan maintained stable GMV, while others like Feicui continued to grow significantly [3][9]. - The collagen medical beauty segment is expanding, with two new animal-derived collagen products approved for market entry, expected to drive growth in this area [3][9]. - The report highlights the leading market share of Minoxidil products from Mandi International in the hair loss treatment market, with a steady revenue growth from 982 million yuan in 2022 to approximately 1.455 billion yuan in 2024, reflecting a CAGR of 21.7% from 2022 to 2024 [10][11]. - L'Oréal's acquisition of an additional 10% stake in Galderma, raising its total ownership to 20%, signifies a strategic shift towards the medical beauty and skin health sectors, aiming to adapt to the slowing growth in the Chinese beauty market [3][18]. Summary by Sections Industry Performance - The Shenwan Beauty Care Index and its sub-indices for cosmetics and personal care products have shown declines of 1.2% and 1.7%, respectively, indicating underperformance compared to the Shenwan A Index [4][6]. Key Market Developments - The overall GMV for cosmetics in November was weak, influenced by earlier sales spikes in October and competition from Douyin [9]. - The approval of new collagen products is expected to enhance the supply side of the medical beauty market, with projections for continued expansion in 2026 [9][22]. Company Highlights - Mandi International has maintained a dominant position in the Minoxidil market, with its products accounting for approximately 57% and 71% of the market share in the hair loss treatment and Minoxidil categories, respectively, as of 2024 [11][13]. - The report notes that the Chinese consumer healthcare market is projected to grow from 931.3 billion yuan in 2018 to 16.42 trillion yuan by 2024, with significant growth in hair health and skin health segments [12][13].

来源：滚动播报 （来源：北京商报） 收购、投资，欧莱雅正在用一切可行的办法扩大版图，抢占市场份额。近日，欧莱雅官方发布消息称， 从由EQT牵头的财团手中收购高德美额外10%的股权。在更早的10月，欧莱雅刚刚斥资40亿欧元拿下开 云集团多个奢侈品品牌美妆授权；11月，欧莱雅再投国产护肤品牌LAN兰……这背后或许是欧莱雅正 在面临的增长放缓现实情况。 增资高德美 此次交易完成后，欧莱雅对高德美的持股比例将增至20%。早在2024年底，欧莱雅收购了高德美10%的 股权。欧莱雅官方披露的信息中，并没有透露此次增持的具体金额。不过欧莱雅方面透露，鉴于投资增 加，高德美董事会将考虑从2026年年度股东大会起，提名2名来自欧莱雅的非独立董事候选人，以取代 由EQT领导的财团。 高德美是一家专业的皮肤科学公司，专注于护肤品和医美赛道。2024年3月，高德美在瑞士证券交易所 正式敲钟上市。目前，高德美的业务领域包括注射美学、皮肤护理和皮肤治疗三个板块，旗下品牌组合 包括瑞蓝、吉适、Azzalure等注射美学品牌，丝塔芙和Alastin等日常护肤品牌，以及Soolantra、 Epiduo、达芙文等皮肤治疗品牌，公司业务遍及约9 ...

FLEER CA 本 20 HELENA RUBINSTEIN 增资高德美 收购、投资，欧莱雅正在用一切可行的办法扩大版图，抢占市场份额。近日，欧莱雅官方发布消息称，从由EQT牵头的财团手中收购高德美额外10%的股 权。在更早的10月，欧莱雅刚刚斥资40亿欧元拿下开云集团多个奢侈品品牌美妆授权；11月，欧莱雅再投国产护肤品牌LAN兰……这背后或许是欧莱雅正 在面临的增长放缓现实情况。 此次交易完成后，欧莱雅对高德美的持股比例将增至20%。早在2024年底，欧莱雅收购了高德美10%的股权。欧莱雅官方披露的信息中，并没有透露此次增 持的具体金额。不过欧莱雅方面透露，鉴于投资增加，高德美董事会将考虑从2026年年度股东大会起，提名2名来自欧莱雅的非独立董事候选人，以取代由 EQT领导的财团。 欧莱雅看中的不只是医美赛道。近年来，欧莱雅正在构建足够涵盖高奢、大众、护肤、美发等全场景的美妆体系。不论是对医美赛道的势在必得，还是对高 奢美妆的加持，以及对中国更具发展潜力的护肤品牌的投资，都在推动欧莱雅向更丰富的阵容、更完整的版图挺进。 今年10月，欧莱雅宣布与开云集团在高端美容与健康领域建立长期战略合作关系，涉及收购Cr ...

Core Viewpoint - The Chinese medical beauty market is rapidly expanding, with a market size of 217.9 billion yuan in 2021, projected to exceed 1 trillion yuan by 2030. The "perioperative skincare" segment is gaining traction, attracting over 20 beauty companies to enter the field [2]. Group 1: Market Expansion and Trends - The "perioperative skincare" segment is a professional blue ocean attracting major beauty brands, with international giants and emerging brands competing for growth [2]. - The concept of "holistic skincare" was first introduced by SkinCeuticals in China in 2012, establishing a scientific system and comprehensive product matrix in the perioperative skincare field [4]. Group 2: Academic Leadership and Events - SkinCeuticals has been invited to the IMCAS conference for 12 consecutive years, showcasing its academic strength and industry leadership through various dimensions [3]. - The IMCAS conference featured a satellite meeting led by Professor Xiang Lei Hong from Fudan University, discussing global trends in medical beauty and advancements in holistic skincare [6]. Group 3: Holistic Skincare Development - SkinCeuticals has established a mature "dual beauty" concept system under the holistic skincare philosophy, setting standardized guidelines for the industry [8]. - The brand emphasizes the synergy between effective skincare products and medical beauty projects, supported by clinical research and global case studies [9]. Group 4: Innovations and Product Launches - SkinCeuticals is expanding the holistic skincare concept into holistic aesthetics with the launch of the "SkinCeuticals Collagen Injection," the only human-derived collagen solution certified as a Class III medical device in China [15]. - The introduction of the A.G.E. serum, featuring 30% progerin solution and five patented anti-glycation technologies, highlights the brand's commitment to advanced anti-aging solutions [23]. Group 5: Industry Challenges and Solutions - The medical beauty industry faces challenges such as excessive marketing and misinformation, which can lead to safety risks for consumers [19]. - A roundtable forum was held to discuss the core needs of consumers and explore solutions to industry pain points, emphasizing a return to scientific principles in anti-aging practices [21].